J&J hikes 2021 profit forecast, COVID-19 vaccine sales grow

Posted 10/19/21

Sales of the cancer treatment Darzalex helped Johnson & Johnson deliver better-than-expected third-quarter earnings, while COVID-19 fueled vaccine revenue and had more customers reaching for …

To Our Valued Readers –

Visitors to our website will be limited to five stories per month unless they opt to subscribe. The five stories do not include our exclusive content written by our journalists.

For $5.99, less than 20 cents a day, digital subscribers will receive unlimited access to YourValley.net, including exclusive content from our newsroom and access to our Daily Independent e-edition.

Our commitment to balanced, fair reporting and local coverage provides insight and perspective not found anywhere else.

Your financial commitment will help to preserve the kind of honest journalism produced by our reporters and editors. We trust you agree that independent journalism is an essential component of our democracy. Please click here to subscribe.

Sincerely,
Charlene Bisson, Publisher, Independent Newsmedia

Please log in to continue

Log in
I am anchor

J&J hikes 2021 profit forecast, COVID-19 vaccine sales grow

Posted

Sales of the cancer treatment Darzalex helped Johnson & Johnson deliver better-than-expected third-quarter earnings, while COVID-19 fueled vaccine revenue and had more customers reaching for Tylenol.

The world’s biggest maker of health care products hiked its 2021 earnings forecast after saying Tuesday that net income climbed 3% to $3.67 billion in the recently completed quarter.

Sales of the company's single-shot COVID-19 vaccine started to pick up in the quarter and nearly doubled what it brought in during the first half of 2021.

J&J also said that sales of over-the-counter drugs, which do not need prescriptions, grew 18% globally as more customers bought Tylenol and Motrin partly because they wanted vaccine symptom relief.

Injections of COVID-19 vaccines, which have been widely available since spring, can come with side effects like arm soreness or a temporary fever.

J&J rang up $502 million in sales from its COVID-19 vaccine in the third quarter after pulling in $264 million during the first half of 2021.

The New Brunswick, New Jersey, company’s vaccine started slow earlier this year. Its rollout was hurt by manufacturing complications and concern about rare side effects, including a blood clot disorder.

But company leaders expect sales to pick up and total around $2.5 billion for the year. The company has said it doesn't intend to profit from the shots.

Last Friday, Food and Drug Administration advisers endorsed booster shots of the vaccine like they did for other shots from rivals Pfizer and Moderna. The FDA still has to decide whether to authorize the extra shots. Then the Centers for Disease Control and Prevention will weigh in on who should get them.

Outside vaccines, sales of J&J's multiple myeloma treatment Darzalex jumped 44% in the quarter to $1.58 billion. That helped revenue from the company’s largest business, pharmaceuticals, grow about 14% to nearly $13 billion.

Sales from J&J’s medical device segment grew 8% to $6.64 billion, even though a surge in COVID-19 cases prompted doctors and hospitals to postpone some non-emergency procedures like knee surgeries during the quarter.

Overall, J&J’s adjusted earnings totaled $2.60 per share while sales grew nearly 11% to $23.34 billion.

Analysts expected, on average, earnings of $2.35 per share on $23.64 billion in revenue, according to FactSet.

J&J now forecasts 2021 adjusted earnings to range between $9.77 and $9.82 per share. The company also tightened its expectation for operational sales, which exclude the impact of currency exchange rates, to $92.8 billion to $93.3 billion.

Analysts forecast, on average, earnings of $9.71 per share on $94.36 billion in sales.

Shares of J&J climbed more than 2% to $164.25 in late-morning trading. The Dow Jones Industrial Average, of which J&J is a component, rose slightly.

___

Follow Tom Murphy on Twitter:

Comments

No comments on this item Please log in to comment by clicking here